Data-Driven Audio Feature Space Clustering for Automatic Sound Recognition in Radio Broadcast News

This is an Open Access article published by World Scientific Publishing Company. It is distributed under the terms of the Creative Commons Attribution 4.0 (CC-BY) License. Further distribution of this work is permitted, provided the original work is properly cited. T. Theodorou, I. Mpoas, A. Lazaridis, N. Fakotakis, 'Data-Driven Audio Feature Space Clustering for Automatic Sound Recognition in Radio Broadcast News', International Journal on Artificial Intelligence Tools, Vol. 26 (2), April 2017, 1750005 (13 pages), DOI: 10.1142/S021821301750005. © The Author(s).In this paper we describe an automatic sound recognition scheme for radio broadcast news based on principal component clustering with respect to the discrimination ability of the principal components. Specifically, streams of broadcast news transmissions, labeled based on the audio event, are decomposed using a large set of audio descriptors and project into the principal component space. A data-driven algorithm clusters the relevance of the components. The component subspaces are used by sound type classifier. This methodology showed that the k-nearest neighbor and the artificial intelligent network provide good results. Also, this methodology showed that discarding unnecessary dimension works in favor on the outcome, as it hardly deteriorates the effectiveness of the algorithms.Peer reviewe

Detection violent behaviors: A survey

Violence detection behavior is a particular problem regarding the great problem action recognition. In recent years, the detection and recognition of violence has been studied for several applications, namely in surveillance. In this paper, we conducted a recent systematic review of the literature on this subject, covering a selection of various researched papers. The selected works were classified into three main approaches for violence detection: video, audio, and multimodal audio and video. Our analysis provides a roadmap to guide future research to design automatic violence detection systems. Techniques related to the extraction and description of resources to represent behavior are also reviewed. Classification methods and structures for behavior modelling are also provided.European Structural and Investment Funds in the FEDER component, through the Operational Competitiveness and Internationalization Programme (COMPETE 2020) [Project n ∘ 039334; Funding Reference: POCI-01-0247-FEDER-039334]. This work has been supported by national funds through FCT – Fundação para a Ciência e Tecnologia through project UIDB/04728/202

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

A knowledge engineering approach for complex violence identification in movies

Along with the rapid increase of available multimedia data, comes the proliferation of objectionable content such as violence and pornography. We need efficient tools for automatically identifying, classifying and filtering out harmful or undesirable video content for the protection of sensitive user groups (e.g. children). In this paper we present a multimodal approach towards the identification and semantic analysis of violent content in video data. We propose a layered architecture and focus on ontological and knowledge engineering aspects of video analysis. We demonstrate the development of two ontologies defining violent hints hierarchy that low level analysis, in visual and audio modality, respectively should identify. Violence domain ontology, as a reality representation, defines higher-level semantics. Taking under consideration extracted violent hints, spatio-temporal relations and behavior patterns higher-level semantics automatic inference is possible. © 2007 International Federation for Information Processing

Multimodal and ontology-based fusion approaches of audio and visual processing for violence detection in movies

In this paper we present our research results towards the detection of violent scenes in movies, employing advanced fusion methodologies, based on learning, knowledge representation and reasoning. Towards this goal, a multi-step approach is followed: initially, automated audio and visual analysis is performed to extract audio and visual cues. Then, two different fusion approaches are deployed: (i) a multimodal one that provides binary decisions on the existence of violence or not, employing machine learning techniques, (ii) an ontological and reasoning one, that combines the audio-visual cues with violence and multimedia ontologies. The latter reasons out not only the existence of violence or not in a video scene, but also the type of violence (fight, screams, gunshots). Both approaches are experimentally tested, validated and compared for the binary decision problem of violence detection. Finally, results for the violence type identification are presented for the ontological fusion approach. For evaluation purposes, a large dataset of real movie data has been populated. © 2011 Elsevier Ltd. All rights reserved

Antiinflammatory therapy with canakinumab for atherosclerotic disease

BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). CONCLUSIONS: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. Copyright © 2017 Massachusetts Medical Society